Short acting inhaled bronchodilator will be permitted through out the trial. Asthma lung function exacerbation
Conditions
Interventions
Add on montelukast to ICS group ,Moderate to high dose inhaled corticosteroid group.
Active Comparator Drug,Active Comparator Drug
Montelukast in mild asthma,low dose ICS/LABA in mild asthma
Sponsors
Faculty of medicine CMU
Faculty of medicine CMU
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Clinical diagnosed asthma age >= 18 year Treated with low to moderate dose of ICS/LABA Not well control asthma (ACT score < 20 or physician diagnosed as not well controlled asthma
Exclusion criteria
Exclusion criteria: History of severe exacerbation including hospitalization / ER visit in the precious year. Pregnancy or child bearing. Subjects who were treated with systemic steroid in the previous 6 months. Subjects who were treated with LAMA. Subjects who were treated with montelukast in the last 3 months. age >= 80 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| acute exarcerbation of asthma 12 months time per year | — |
Secondary
| Measure | Time frame |
|---|---|
| ACT score 12 months point every 3 months,PFT parameter 12 months point every 3 months | — |
Countries
Thailand
Outcome results
None listed